Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Smoldering multiple myeloma.

Prasad HK, Zhan F, Shaughnessy J.

N Engl J Med. 2007 Sep 6;357(10):1048; author reply 1049-50. No abstract available.

2.

Gene expression profiling and multiple myeloma.

Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK.

Best Pract Res Clin Haematol. 2005;18(4):537-52. Review.

PMID:
16026736
3.

Insights from the gene expression profiling of multiple myeloma.

Claudio JO, Masih-Khan E, Stewart AK.

Curr Hematol Rep. 2004 Jan;3(1):67-73. Review.

PMID:
14695854
4.

Gene expression profiling defines a high-risk entity of multiple myeloma.

Zhan FH, Barlogie B, John D S Jr.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007 Apr;32(2):191-203. Review.

5.

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du Myélome.

J Clin Oncol. 2008 Oct 10;26(29):4798-805. doi: 10.1200/JCO.2007.13.8545. Epub 2008 Jun 30.

PMID:
18591550
6.

Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling.

Zhan F, Barlogie B, Shaughnessy J Jr.

Semin Hematol. 2003 Oct;40(4):308-20. Review.

PMID:
14582081
7.

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

Stewart AK, Fonseca R.

J Clin Oncol. 2005 Sep 10;23(26):6339-44. Review.

PMID:
16155017
8.

Prognostic factors in multiple myeloma.

Tricot G.

Clin Adv Hematol Oncol. 2005 Mar;3(3):167-8. No abstract available.

PMID:
16166987
9.

Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.

Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R.

Cancer Res. 2007 Apr 1;67(7):2982-9.

10.
11.

Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.

Rosiñol L, Carrió A, Bladé J, Queralt R, Aymerich M, Cibeira MT, Esteve J, Rozman M, Campo E, Montserrat E.

Br J Haematol. 2005 Sep;130(5):729-32.

PMID:
16115129
12.

Gene profiling of lymphoma, myeloma, and AML.

Rogge L, Bianchi E.

MedGenMed. 2003 Jul 24;5(3):12. Review. No abstract available.

13.

Further insights into multiple myeloma genetics.

Drach J.

Haematologica. 2006 Feb;91(2):147a. No abstract available.

PMID:
16461292
14.

The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma.

Sarasquete ME, García-Sanz R, Armellini A, Fuertes M, Martín-Jiménez P, Sierra M, Del Carmen Chillón M, Alcoceba M, Balanzategui A, Ortega F, Hernández JM, Sureda A, Palomera L, González M, San Miguel JF.

Haematologica. 2006 Nov;91(11):1551-4. Epub 2006 Oct 17.

15.

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B.

Blood. 2009 Jun 25;113(26):6572-5. doi: 10.1182/blood-2009-02-207803. Epub 2009 Apr 23.

16.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr.

Blood. 2002 Mar 1;99(5):1745-57.

17.

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B.

Br J Haematol. 2007 Jun;137(6):530-6. Epub 2007 May 9.

PMID:
17489983
18.

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.

Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ.

Blood. 2007 Nov 1;110(9):3291-300. Epub 2007 Jul 3.

19.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Rajkumar SV, Lacy MQ, Kyle RA.

Blood Rev. 2007 Sep;21(5):255-65. Epub 2007 Mar 26. Review.

PMID:
17367905
20.

Genomics and proteomics in multiple myeloma and Waldenström macroglobulinemia.

Henry T, Fonseca R.

Curr Opin Hematol. 2007 Jul;14(4):369-74. Review.

PMID:
17534163

Supplemental Content

Support Center